nach oben

Erschienen in:

30.10.2017 | COPD | FORTBILDUNG . ÜBERSICHT

Lassen Sie Ihre Patienten wieder freier atmen!

Aktuelle Therapieoptionen bei der COPD

verfasst von: Prof. Dr. med. A. Gillissen, M.Sc., Univ.-Prof. Dr. med. univ. Christian M. Kähler, Prof. Dr. med. A. Rembert Koczulla, Dr. med. Rüdiger Sauer, Dr. med. Maria Paparoupa

Erschienen in: MMW - Fortschritte der Medizin | Sonderheft 3/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die chronisch-obstruktive Lungenerkrankung (COPD) wurde lange Zeit als eine Erkrankung der Atemwege und der Lunge mit irreversiblen Veränderungen des Lungenparenchyms (Lungenemphysem) und einer nicht oder nur schwer behandelbaren Atemwegsobstruktion angesehen. Dieses Bild hat sich bis heute grundlegend geändert.

Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389:1931–40CrossRefPubMed

Committee GE. Global initiative for chronic obstructive lung disease. www goldcopd com 2017

Lopez AD, Murray CC. The global burden of diseases. Natur Med. 1998;4:1241–3CrossRef

Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet. 1997;349:1269–76CrossRefPubMed

Geldmacher H, Biller H, Herbst A et al. Die Prävalenz der chronisch-obstruktiven Lungenerkrankung (COPD) in Deutschland. Dtsch Med Wschr. 2008;133:2609–14CrossRefPubMed

Gillissen A, Lommatzsch M, Prenzler A et al. Chronisch obstruktive Lungenerkrankung (COPD). In: Gillissen A, Welte T, Hrsg. Weißbuch Lunge 2014 Die Lunge und ihre Erkrankungen: Zur Lage und Zukunft der Pneumologie ind Deutschland. 1. Aufl. Herne: Frischtexte Verlag; 2014:47–57

Glaser S, Schaper C, Obst A et al. Impact of different definitions of airflow limitation on the prevalence of chronic obstructive pulmonary disease in the general population. Respiration. 2010;80:292–300CrossRefPubMed

Varkey AB. Chronic obstructive pulmonary disease in women: exploring gender differences. Curr Opin Pulm Med. 2004;10:98–103CrossRefPubMed

Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J. 2009;34:757–69CrossRefPubMed

10.

Beeh KM, Beier J. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways disease. Adv Ther. 2009;26:691–9CrossRefPubMed

11.

Andrus MR, Loyed JV. Use of beta-adrenoceptor antagonists in older patients with chronic obstrucitve pulmonary disease and cardiovascular co-morbidity: safety issues. Drugs Aging. 2008;25:131–44CrossRefPubMed

12.

Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest 2008;133: 1079–87CrossRefPubMed

13.

Taylor MRG. Pharmacogenetics of the human beta-adrenergic receptors. Pharmacogenomics J. 2007;7:29–37CrossRefPubMed

14.

Brunson M, Bailey WC. Anticholinergics. In: Pauwels RA, Postma DS, Weiss ST, Hrsg. Lung biology in health and disease. 1. Aufl. New York: Marcel Dekker; 2005:353–82

15.

Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093–103CrossRefPubMed

16.

Hilleman DE, Malesker MA, Morrow LE et al. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int J COPD. 2009;4:253–63CrossRef

17.

Kesten S, Celli BR, Decramer M et al. Tiotropium handiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis. 2009;4:397–409CrossRefPubMedPubMedCentral

18.

Salpeter SR. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events ? A synthesis of the available evidence. Drugs. 2009;69:2025–33CrossRefPubMed

19.

(ÄZQ) ÄZfQidM. Nationale Versorgungsleitlinie COPD. In: Bundesärztekammer (BÄK) AdWMFA, Bundesä eds; www.ersorgungsleitlinien.de. 1.8 ed; 2011:1–99

20.

Committee GEaS. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: National Institutes of Health, World Health Organization; 2017; www.ginasthma.org

21.

Wedzicha JA. Choice of bronchodilator therapy for patients with COPD. N Engl J Med. 2011;364:1167–8CrossRefPubMed

22.

Gillissen A, Kahler CM, Koczulla AR et al. Chronisch obstruktive Lungenerkrankung: So setzen Sie die aktualisierten GOLD-Empfehlungen um. MMW Fortschr Med. 2017;159(12):56–9CrossRefPubMed

23.

Gillissen A, Haidl P, Kohlhäufl M et al. The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. Dtsch Arztebl Int. 2016;113:311–6PubMedPubMedCentral

24.

Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45:525–37CrossRefPubMed

25.

Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;3: CD010115

26.

Battaglia S, Cardillo I, Lavorini F et al. Safety considerations of inhaled corticosteroids in the elderly. Drugs Aging. 2014;31:787–96CrossRefPubMed

27.

Subramanian, Ragulan, Jindal A et al. The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD. J Clin Diagn Res. 2015;9:OC10–3PubMedPubMedCentral

28.

Chen CY, Yang KY, Lee YC et al. Effect of oral aminophylline on pulmonary function improvement and tolerability in different age groups of COPD patients. Chest. 2005;128:2088–92CrossRefPubMed

29.

Rabe KF, Dent G, Magnussen H. Pharmakodynamik des Theophyllins. In: Ukena D, Keller A, Nolte D, Hrsg. Theophyllin - Controller and Reliever bei Asthma und COPD. München-Deisenhofen: Dustri-Verlag Dr. Karl Feistle; 1999:1–39

30.

Gillissen A. Bewertung der Theophyllin-Therapie beim Asthma bronchiale. MMW Fortschr Med. 1997;139

31.

Fexer J, Donnachie E, Schneider A et al. The effects of theophylline on hospital admissions and exacerbations in COPD patients: audit data from the Bavarian disease management program. Dtsch Arztebl Int. 2014;111:293–300PubMedPubMedCentral

32.

Martinez FJ, Calverley PM, Goehring UM et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–66CrossRefPubMed

33.

Wedzicha JA, Rabe KF, Martinez FJ et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013;143:1302–11CrossRefPubMed

34.

Fabbri LM, Calverley PMA, Izquierdo-Alonso JL et al. Roflumilast in moderate to severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised trials. Lancet. 2009;374:695–703CrossRefPubMed

35.

Rabe KF, Calverley PMA, Martinez FJ et al. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J. 2017;50

36.

Worth H, Buhl R, Criee CP et al. The ‚real-life‘ COPD patient in Germany: The DACCORD study. Respir Med. 2016;111:64–71CrossRefPubMed

37.

Simeone JC, Luthra R, Kaila S et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis. 2017;12:73–83CrossRefPubMed

38.

Montuschi P, Malerba M, Macis G et al. Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discov Today. 2016;21:1820–7CrossRefPubMed

39.

Wedzicha JA, Singh D, Vestbo J et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108:1153–62CrossRefPubMed

40.

Pascoe S, Locantore N, Dransfield MT et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435–42CrossRefPubMed

41.

Pascoe SJ, Lipson DA, Locantore N et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48:320–30CrossRefPubMed

42.

Singh D, Papi A, Corradi M et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963–73CrossRefPubMed

43.

Lim HS, Choi SM, Lee J et al. Responsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndrome. Ann Allergy Asthma Immunol. 2014;113:652–7CrossRefPubMed

44.

Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. Thorax 2015, DOI: thoraxjnl-2014-206740 [pii];10.1136/thoraxjnl-2014-206740 [doi]

45.

Watz H, Tetzlaff K, Wouters EF et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016, DOI: 10.1016/S2213-2600(16)00100-4

46.

Voshaar T, Idzko M, Münks-Lederer C et al. Einsatz inhalativer Mono- und Kombinationstherapien. Dtsch Arztebl. 2016;113(24):4

47.

Gillissen A. Tatsächliche Güte der Asthmaeinstellung und Möglichkeiten der zukünftigen Therapieoptimierung. Pneumologie. 2015;69:36–47CrossRefPubMed

48.

Gillissen A. Patientenpräferenz von Inhalern. Pneumologie. 2015;68:727–36

49.

Voshaar T, App EM, Berdel D et al. Empfehlungen für die Auswahl von Inhalationssystemen zur Medikamentenverabreichung. Pneumologie. 2002;55:579–86CrossRef

50.

Worth H, Schacher C, Dethlefsen U. Concomitant therapy with cineole (eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial. Resp Research 2009;10:70–2; https://doi.org/10.1186/1465-9921-1110-1169CrossRef

51.

Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003;2:CD001287

52.

Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ. 2001;322:1–6CrossRef

53.

Jund R, Mondigler M, Stammer H et al. Herbal drug BNO 1016 is safe and effective in the treatment of acute viral rhinosinusitis. Acta Otolaryngol. 2015;135:42–50CrossRefPubMedPubMedCentral

54.

Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–8CrossRefPubMedPubMedCentral

55.

Marciniuk DD, Hernandez P, Balter M et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2012;19:109–16CrossRefPubMedPubMedCentral

56.

Rahaghi FF, Miravitlles M. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence. Respir Res. 2017;18:105CrossRefPubMedPubMedCentral

57.

Bernhard N, Bals R, Fahndrich S. Alpha-1-Antitrypsinmangel - was gibt es Neues ? Dtsch Med Wochenschr. 2016;141:1467–9CrossRefPubMed

58.

Chapman KR, Burdon JG, Piitulainen E et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:360–8CrossRefPubMed

59.

Greulich T. Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies. COPD. 2017;14:8–11CrossRef

60.

Greulich T, Nell C, Hohmann D et al. The prevalence of diagnosed alpha1-antitrypsin deficiency and its comorbidities: results from a large population-based database. Eur Respir J. 2017;49:pii 600154CrossRef

61.

Greulich T, Averyanov A, Borsa L et al. European screening for alpha1 -antitrypsin deficiency in subjects with lung disease. Clin Respir J. 2017;11:90–7CrossRefPubMed

62.

Andreas S, Batra A, Behr J et al. Tabakentwöhnung bei COPD. S3 Leitlinie herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin. Pneumologie. 2008;62:255–72CrossRefPubMed

63.

Makris D, Moschandreas J, Damianaki A et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007;101:1305–12CrossRefPubMed

64.

Anthonisen NR, Skeans M, Wise RA et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233–9CrossRefPubMed

65.

Scanlon PD, Connett JE, Waller LA et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000;161:381–90CrossRef

66.

Tremblay M, Gervais A, Lacroix C et al. Physicians taking action against smoking: an intervention program to optimize smoking cessation counselling by Montrealgeneral practitioners. CMAJ 2001;165:601–7PubMedPubMedCentral

67.

Boeselt T, Nell C, Lutteken L et al. Benefits of High-Intensity Exercise Training to Patients with Chronic Obstructive Pulmonary Disease: A Controlled Study. Respiration. 2017;93:301–10CrossRefPubMed

68.

Spielmanns M, Meier A, Winkler A et al. Eine pneumologische Rehabilitation nach akuter Exazerbation der COPD senkt die Rate erneuter Exazerbationen. Dtsch Med Wochenschr. 2017;142:e10–19CrossRefPubMed

69.

Boeselt T, Spielmanns M, Nell C et al. Validity and Usability of Physical Activity Monitoring in Patients with Chronic Obstructive Pulmonary Disease (COPD). PLoS One 2016;11:e0157229CrossRefPubMedPubMedCentral

70.

Vogelmeier C, Buhl R, Criee C-P et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie. 2007;61:e1–40CrossRefPubMed

71.

Petro W, Buhr-Schinner H, Taube K et al. Rehabilitation bei COPD. Pneumologie 2007;61:384–92CrossRefPubMed

72.

Wittmann M, Spohn S, Schultz K et al. COPD-Schulung im Rahmen der stationären Rehabilitation verbessert Lebensqualität und Morbidität. Pneumologie. 2007;61:636–42CrossRefPubMed

73.

Gerardi D, ZuWallack R. Non-pulmonary factors affecting survival in patients completing pulmonary rehabilitation. Monaldi Arch Chest Dis. 2001;56:331–5PubMed

74.

Magnussen H, Kirsten A-M, Köhler D et al. Leitlinien zur Langzeit-Sauerstofftherapie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V. Pneumologie. 2008;62:748–56CrossRefPubMed

75.

Long-Term Oxygen Treatment Trial Research G, Albert RK, Au DH et al. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med. 2016;375:1617–27CrossRef

76.

Gorecka D, Gorzelak K, Sliwinski P et al. Effect of long term oxygen therapy on survival in patients with chronic obstrucitve airway disease. Thorax. 1997;52:674–9CrossRefPubMedPubMedCentral

77.

Windisch W, Brambring J, Budweiser S et al. Nichtinvasive und invasive Beatmung als Therapie der chronischen respiratorischen Insuffizienz. Pneumologie. 2010;64:207–40CrossRefPubMed

78.

Randerath W, Lorenz J, Windisch W et al. Betreuung von Patienten mit maschineller Beatmung unter häuslichen und heimpflegerischen Bedingungen. Pneumologie. 2008;62:305–8CrossRefPubMed

79.

Group NETR, National. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059–73CrossRef

80.

Strange C, Herth FJ, Kovitz KL et al. Design of the endobronchial valve for emphysema palliation trial (VENT): a non-surgical method of lung volume reduction. BMC Pulmonary Medicine. 2007;7:10CrossRefPubMedPubMedCentral

81.

Shah PL, Herth FJ, van Geffen WH et al. Lung volume reduction for emphysema. Lancet. Respir Med. 2017;5:147–56CrossRefPubMed

82.

Gompelmann D, Eberhardt R, Herth F. Endoscopic volume reduction in COPD- a critical review. Dtsch Arztebl Int. 2014;111:827–33PubMedPubMedCentral

83.

McKenna JRJ. Endobronchial valves for the treatment of emphysema. Semin Thorac Cardiovasc Surg. 2008;20:285–9CrossRefPubMed

84.

Sciurba FC, Criner GJ, Strange C et al. Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. JAMA. 2016;315: 2178–89CrossRefPubMed

85.

Shah PL, Gompelmann D, Valipour A et al. Thermal vapour ablation to reduce segmental volume in patients with severe emphysema: STEP-UP 12 month results. Lancet Respir Med. 2016;4:e44–5CrossRefPubMed

86.

Herth FJ, Valipour A, Shah PL et al. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. Lancet Respir Med. 2016;4:185–93CrossRefPubMed

87.

Gompelmann D, Eberhardt R, Herth FJ. Technology update: bronchoscopic thermal vapor ablation for managing severe emphysema. Med Devices (Auckl). 2014;7:335–41CrossRef

88.

Budweiser S, Jörres RA, Pfeifer M. Noninvasive home ventilation for chronic obstructive pulmonary disease: indications, utility and outcome. Curr Opin Pulm Med. 2008;14:128–34CrossRefPubMed

89.

Ambrosino N, Vagheggini G. Noninvasive positive pressure ventilation in the acute care setting: where are we? Eur Respir J 2008;31:874–86CrossRefPubMed

90.

Keenan SP, Gregor J, Sibbald WJ et al. Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more effective and less expensive. Crit Care Med. 2000;28:2094–102CrossRefPubMed

Titel: Lassen Sie Ihre Patienten wieder freier atmen!
Aktuelle Therapieoptionen bei der COPD
verfasst von: Prof. Dr. med. A. Gillissen, M.Sc.
Univ.-Prof. Dr. med. univ. Christian M. Kähler
Prof. Dr. med. A. Rembert Koczulla
Dr. med. Rüdiger Sauer
Dr. med. Maria Paparoupa
Publikationsdatum: 30.10.2017
Verlag: Springer Medizin
Schlagwörter: COPD
Lungenemphysem
Erschienen in: MMW - Fortschritte der Medizin / Ausgabe Sonderheft 3/2017
Print ISSN: 1438-3276
Elektronische ISSN: 1613-3560
DOI: https://doi.org/10.1007/s15006-017-9594-5

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 3/2017

Frühzeitig Mahlzeiteninsulin — das hilft bei Insulinresistenz

I.v. Eisen stärkt das Herz

Neue EBM-Ziffern für die Cannabisverordnung

Alpha-1-Antitrypsinmangel rechtzeitig behandeln

Der Laborbonus rinnt durch die Finger

Mittelfußschmerz bei jedem Spaziergang